Key Finding
Patients with knee osteoarthritis who received electrical dry needling booster sessions every 4 weeks maintained significantly greater improvements in pain and function with large effect sizes (SMD=1.32) compared to less frequent or no maintenance treatment over 30 weeks.
Researchers studied whether regular "booster" sessions of a specialized dry needling technique could help people with knee osteoarthritis maintain pain relief over time. The study involved 586 patients who first received periosteal and intraarticular electrical dry needling (PIEDN) treatments 1-2 times per week for six weeks. After this initial treatment phase, patients were divided into three groups: one received booster sessions every 4 weeks, another every 8 weeks, and a third received no additional treatment. All groups were then followed for 30 weeks to see how well their improvements lasted.
The results showed clear differences between the groups. Patients who received booster treatments every 4 weeks maintained significantly better outcomes in pain, stiffness, function, and overall disability compared to those who received boosters less frequently or not at all. The improvements were substantial—63% of patients in the every-4-weeks group were able to completely stop their pain medications by the end of the study, compared to only 21% in the no-treatment group. The effect sizes were large, meaning the differences were clinically meaningful and not just statistical.
For patients with knee osteoarthritis considering this treatment approach, these findings suggest that consistent maintenance care matters. While an initial series of treatments can provide relief, regular booster sessions every month appear necessary to sustain those benefits over the longer term. This differs from a one-time treatment approach and requires ongoing commitment. If you're considering electrical dry needling for knee osteoarthritis, seek a qualified practitioner trained in this specific technique to ensure safe and effective treatment.
This multi-center RCT (n=586) investigated optimal dosing intervals for periosteal and intraarticular electrical dry needling (PIEDN) maintenance therapy in knee osteoarthritis patients. Following an initial 6-week treatment phase (1-2 sessions/week), patients were randomized to receive PIEDN boosters every 4 weeks (n=195), every 8 weeks (n=197), or no further treatment (n=194) for 6 months. Primary outcome was the WOMAC Index.
Results demonstrated significant superiority of the 4-week booster interval across all measures. The PIEDN-4 group showed large between-group effect sizes at 30 weeks for WOMAC total score (SMD=1.32; 95% CI: 1.10, 1.54) and pain (NPRS SMD=1.14; 95% CI: 0.93, 1.36). Statistically significant improvements were observed in disability (F=33.060; p<.001), pain (F=25.678, p<.001), stiffness (F=27.416, p<.001), and physical function (F=32.856; p<.001). Notably, 63.1% of PIEDN-4 patients discontinued medication versus 21.1% in controls (p<.001).
Clinical takeaway: Monthly PIEDN booster sessions are necessary to maintain therapeutic gains in knee OA management, with treatment frequency directly correlating to sustained clinical outcomes.
Browse our directory of verified licensed practitioners near you.
Find a practitioner →📌 Modified acupuncture techniques, including electroacupuncture and needle-knife therapy, significantly reduced TNF-α levels in knee osteoarthritis patients compared to traditional acupuncture (SMD = -1.63, p < 0.01), with moderate GRADE evidence supporting this effect.
📌 The Bushen Tongdu external treatment combining full-channel moxibustion and acupoint catgut embedding achieved a 90.6% effective rate in kidney-yang deficiency type ankylosing spondylitis, significantly outperforming salazosulfapyridine on BASDAI scores and serum inflammatory markers IL-6, TNF-α, and MMP-3.
📌 Acupuncture, particularly as adjunct therapy, significantly reduced pain, morning stiffness, and key inflammatory markers including CRP, ESR, and pro-inflammatory cytokines in patients with ankylosing spondylitis across 52 randomized controlled trials.